trending Market Intelligence /marketintelligence/en/news-insights/trending/j1imt_mczwwg7o8un71sia2 content esgSubNav
In This List

Viking Therapeutics plans common stock offering to advance clinical programs

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Viking Therapeutics plans common stock offering to advance clinical programs

Viking Therapeutics Inc. said it is planning an underwritten public offering of common stock.

The San Diego-based biopharmaceutical company intends to grant the underwriters a 30-day option to buy up to an additional 15% of the shares in the offering.

Viking plans to use net proceeds to develop its programs called VK5211, VK0214 and VK2809 — a potential treatment for a rare genetic disease known as glycogen storage disease type Ia. Proceeds will also be used for general research and development, working capital and general corporate purposes.

William Blair & Co. LLC is acting as sole book-running manager for the proposed offering.